[Nicergoline and platelet aggregation. A review of experimental and clinical studies (author's transl)].
10-Methoxy-1,6-dimethyl-ergoline-8 beta-methanol-(5-bromonicotinate) (nicergoline, Sermion), an ergoline derivative in clinical use for syndromes related to cerebral and peripheral vascular insufficiency, displays a platelet antiaggregating effect which may be important for its therapeutic effect. This paper reviews the present experimental and clinical evidence relating to the platelet antiaggregating activity of nicergoline and its mechanisms of action is discussed in detail. Since the platelet antiaggregating effect of nicergoline is mainly related to its alpha-adrenolytic activity, the importance of catecholamines for the behaviour of both human platelets and endothelium as well as their interference with the prostaglandin/prostacycline system is also discussed.